- Founder: Robert Lefkowitz
- Founded: 2007
- Headquarters: Chesterbrook, Pennsylvania
- trevena.com
** charts before earnings **
** charts after earnings **
- Co reports Q4 EPS of ($0.24) vs ($0.27) Capital IQ Consensus; co did not report any revs
- In January 2018, the Company announced that the FDA has accepted the Company's NDA for OLINVO. OLINVO is an investigational product for the management of moderate to severe acute pain. It is the first G protein biased ligand of the mu receptor designed to provide IV opioid pain relief with fewer associated adverse effects. The FDA has informed the Company that it intends to convene an advisory committee meeting to discuss the OLINVO NDA ahead of the Prescription Drug User Fee Act review date of November 2, 2018. If approved, the Company expects commercial launch of OLINVO in the first quarter of 2019 following DEA scheduling.
Key stats and ratios
| Q3 (Sep '17) | 2016 | |
| Net profit margin | - | -2746.51% |
| Operating margin | - | -2727.55% |
| EBITD margin | - | -2720.99% |
| Return on average assets | -72.82% | -71.03% |
| Return on average equity | -125.32% | -92.91% |
| Employees | 72 |
No comments:
Post a Comment